Relevance. MI is one of the main reasons of CHF development. After revascularization reperfusion of myocardium can invoke clinically significant enlargement of necrosis area. This situation requires pharmacological correction by cardioprotectors, yet they do have side effects. Use of directed delivery of medicinal products is possible to prevent the possibility of adverse effects. Objective. Consider the possibility of use of silica nanoparticles (SNP) as nanocarrier for the delivery of adenosine to ischemic myocardium. Materials and methods. Within the scope of study, the following experimental researches were planned: study of biodistribution of SNP suspension with immobilized fluorophores of fluorescein sodium (FLS-Na) and indocyanine green (ICG), in vitro and in vivo study of SNP biodegradation, influence of adsorbed adenosine infusion at SNP on BP in comparison with effects of free adenosine in the equivalent dose, assessment of infarction-limiting effect of free adenosine and adenosine adsorbed to SNP in the equivalent dose. Results. The finding of the study confirmed satisfactory biodegradation of the nanoparticle suspension in the in vitro experiment and in intravenous introduction of nanopartices in vivo. The study SNP biodistribution showed predominant accumulation in reticuloendothelial organs. It was demonstrated that adenosine adsorbed in the SNP surface has infarction-limiting effect.